Single-Cell Transcriptomics of Surgical Scar Formation: Mechanisms, Clinical Insights, and Emerging Therapeutics

Abstract

Surgical scar formation is a complex reparative process involving a diverse interplay of cellular and molecular events. Recent advances in single-cell transcriptomics have revolutionized our understanding of the heterogeneity and dynamics underlying scar tissue development, providing unprecedented insights into cell-specific gene expression and intercellular communication. This review synthesizes current evidence on the single-cell landscape of surgical scar formation, elucidating the pathophysiological mechanisms, clinical implications, and potential therapeutic avenues informed by transcriptomic profiling. Emphasis is placed on mechanistic underpinnings, risk stratification, diagnostic advances, management strategies, and the integration of emerging omics-guided therapies into clinical practice.

Introduction

Surgical interventions, while essential for the management of myriad pathological conditions, invariably trigger the wound healing response that culminates in scar formation. Traditionally, understanding scar biology has been limited by bulk tissue analyses, which obscure the nuanced roles of individual cell populations. The advent of single-cell RNA sequencing (scRNA-seq) enables comprehensive dissection of cellular diversity and dynamic gene expression at previously unattainable resolution. This paradigm shift holds transformative potential to inform risk assessment, therapeutic targeting, and personalized management of surgical scarring, a concern of significant morbidity and aesthetic impact in clinical practice.

Epidemiology / Disease Burden

Surgical scars are an unavoidable sequela of operative procedures, with millions of new cases occurring annually worldwide. Although most scars remain asymptomatic and cosmetically acceptable, pathological scarring—such as hypertrophic scars and keloids—affects a subset of patients, leading to pain, pruritus, contractures, and psychological distress. The burden is substantial in populations undergoing high-volume surgeries, including cesarean sections, orthopedic procedures, and trauma repairs. Epidemiological studies suggest a higher incidence in individuals with darker skin phototypes and a familial predisposition, emphasizing the need for stratified prevention and management.

Pathophysiology

Surgical scar formation is orchestrated through three overlapping phases: inflammation, proliferation, and remodeling. Single-cell transcriptomic analyses have delineated distinct subpopulations of fibroblasts, immune cells, endothelial cells, and keratinocytes, each contributing unique gene expression signatures during wound healing.
\nDuring the inflammatory phase, scRNA-seq reveals rapid infiltration of neutrophils and monocyte-derived macrophages, orchestrating cytokine-mediated signaling. In the proliferative phase, myofibroblast differentiation—characterized by upregulation of ACTA2 and extracellular matrix (ECM) synthesis genes—predominates. Remodeling is marked by persistent fibroblast activity and altered ECM turnover, with dysregulation leading to excessive fibrosis. Notably, transcriptomic heterogeneity among fibroblast subsets correlates with the propensity for hypertrophic or keloidal scar formation, implicating specific profibrotic pathways such as TGF-β, Wnt, and Hippo signaling.

Risk Factors

Risk factors for pathological surgical scarring encompass both intrinsic and extrinsic determinants. Genetic predisposition, skin phototype, age, and anatomical site are well-established contributors. Recent single-cell studies have identified individual variability in fibroblast and immune cell transcriptomes, suggesting a molecular basis for differential scar outcomes. Extrinsic factors—such as wound tension, infection, delayed healing, and suboptimal surgical technique—exacerbate aberrant gene expression, promoting fibrosis. Hormonal influences and systemic comorbidities, including diabetes and immunosuppression, further modulate cellular responses as elucidated by transcriptomic profiling.

Clinical Features

Clinically, surgical scars manifest along a spectrum from fine, linear scars to disfiguring hypertrophic or keloidal lesions. Early features include erythema, edema, and induration, evolving over weeks to months into mature scars with variable elevation, pigmentation, and pliability. Pathological scars may present with pain, pruritus, and functional impairment, especially when located over joints or flexural surfaces. Single-cell transcriptomics has facilitated the identification of molecular biomarkers predictive of scar phenotype, enabling early stratification and individualized surveillance strategies.

Diagnosis

Diagnosis of surgical scarring remains primarily clinical, supported by photographic documentation and validated scoring systems such as the Vancouver Scar Scale. However, single-cell transcriptomic signatures are emerging as adjunctive diagnostic tools, capable of distinguishing between physiological and pathological scarring at the molecular level. Integration of scRNA-seq data with spatial transcriptomics and bioinformatics pipelines allows for precise mapping of cellular niches and pathologic gene expression, heralding a shift toward precision diagnosis and risk prediction in postoperative care.

Treatment & Management

Current management of surgical scars includes topical therapies (silicone gels, corticosteroids), intralesional injections, laser therapy, pressure therapy, and surgical revision. The efficacy of these modalities is variable, with recurrence rates for hypertrophic and keloid scars remaining significant. Insights from single-cell transcriptomics are driving the development of targeted therapies aimed at modulating specific cell populations and signaling pathways implicated in fibrogenesis. Personalized treatment algorithms, informed by molecular profiling, are anticipated to enhance therapeutic outcomes and minimize adverse effects.

Recent Advances / Emerging Therapies

Emerging therapeutic strategies leverage single-cell transcriptomic data to identify novel drug targets and repurpose existing agents. Small molecule inhibitors of TGF-β, Wnt, and YAP/TAZ pathways are under investigation, with preclinical studies demonstrating attenuation of fibrotic gene expression and scar formation. Cell-based therapies, including autologous fibroblast transplantation and mesenchymal stem cell-derived exosomes, show promise in modulating the wound microenvironment. Furthermore, gene editing technologies such as CRISPR/Cas9 offer the potential to correct pathogenic mutations and reprogram aberrant cell states identified by scRNA-seq. Ongoing clinical trials are evaluating the safety, efficacy, and scalability of these approaches in diverse surgical populations.

Guideline Recommendations

International guidelines emphasize early intervention, individualized risk assessment, and multidisciplinary management of surgical scarring. The integration of single-cell transcriptomic insights is beginning to inform consensus recommendations, advocating for the use of molecular biomarkers in risk stratification and outcome prediction. Standardized protocols incorporating transcriptomic data into clinical decision-making are anticipated to refine patient selection for emerging therapies, optimize timing of interventions, and improve long-term functional and cosmetic outcomes.

Conclusion

The application of single-cell transcriptomics has fundamentally advanced our understanding of the cellular and molecular mechanisms underpinning surgical scar formation. By unraveling the heterogeneity of wound-healing responses, these technologies enable the identification of novel therapeutic targets, predictive biomarkers, and precision medicine strategies for scar prevention and management. Continued research and clinical translation of single-cell omics are poised to transform the landscape of postoperative care, ultimately improving patient quality of life through tailored, mechanism-based interventions.